FAQ: Clene Inc.'s REPAIR-MS Trial Results at ECTRIMS 2025
Summary
Clene Inc. presented positive results from its REPAIR-MS trial at ECTRIMS 2025, showing that CNM-Au8 significantly improved brain energy metabolism in multiple sclerosis patients. The treatment was safe and well-tolerated, demonstrating potential to slow disease progression by addressing bioenergetic failure in MS.
What is the main announcement from Clene Inc.?
Clene Inc. presented combined REPAIR-MS trial results showing that CNM-Au8 significantly improved brain NAD+/NADH ratios, a key marker of energetic capacity, across relapsing and non-active progressive multiple sclerosis patients at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis.
What is CNM-Au8 and how does it work?
CNM-Au8 is an investigational first-in-class therapy that improves central nervous system cells’ survival and function by targeting mitochondrial function and the NAD pathway while reducing oxidative stress. It addresses bioenergetic failure in neurodegenerative diseases like multiple sclerosis.
Why are these trial results significant?
The results are significant because CNM-Au8 showed significant improvements in brain energy metabolism with correlations between baseline brain energy metabolism and disability, cognition, and motor function. The treatment was safe and well-tolerated, reinforcing its potential to slow disease progression in MS.
Where and when were these results presented?
The results were presented at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2025) in Barcelona.
What types of multiple sclerosis patients were included in the trial?
The trial included both relapsing and non-active progressive multiple sclerosis patients, with CNM-Au8 showing significant improvements in brain NAD+/NADH ratios across both patient groups.
What is Clene Inc.’s focus and what other diseases are they targeting?
Clene Inc. is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis.
Where can I find more information about Clene Inc.?
More information is available at www.clene.com, on X (formerly Twitter) at @clenenano, and on LinkedIn at Clene Nanomedicine. The full press release can be viewed at https://ibn.fm/uuEAj.
What safety profile was reported for CNM-Au8?
CNM-Au8 was reported to be safe and well-tolerated in the REPAIR-MS trial, reinforcing its potential as a treatment for multiple sclerosis patients.
Where is Clene Inc. based and where are their operations located?
Clene Inc. is based in Salt Lake City, Utah, with research and development and manufacturing operations in Maryland.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 221715